Research Breakthrough Background
The scientific community discovered the biological properties of rare
ginsenosides about 30 years ago. In recent years, continued in-depth studies proved that rare
ginsenosides play a positive role in enhancing health and improving life quality.
Research Dilemma 1
People have realized the great value of rare ginsenosides for a long time, but rare
ginsenosides are very difficult to obtain for two main reasons: 1) Rare ginsenoside
contents in Araliaceae ginseng species are almost undetectable, even after heat
processing, the extraction rate of ginsenosides reaches only 1/100,000 - 1/10,000; 2)
Rare ginsenosides cannot be made in large quantities through industrialized
preparations, due to the high cost of raw materials and the immaturity of preparation
methodologies.
Research Dilemma 2
Ginsenosides in their natural-occurring forms (prototype ginsenosides R1, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Rg1 etc.), cannot be directly absorbed by the human body. They must first undergo proper gastrointestinal metabolisms and be converted into rare ginsenosides before effective absorption could take place.
Research Dilemma 3
rare ginsenosides are neither water-soluble nor lipid-soluble, and traditional dispersion technology of preparation cannot achieve optimal absorption and utilization.
Four Core Technologies Owned by
Canada Royal Enoch
Canada Royal Enoch
Canada Royal Enoch Phytomedicine Ltd., engaged in phytomedicine research for over 10 years,
eventually conquered the difficulties in extraction, processing, transformation, and
formulation
of ginseng extracts and invented 4 core technologies. Our GMP standard manufacturing
workshop,
located in Vancouver, Canada, is capable of industrialized production. Our products have
already
benefited users from North America and Europe.
Research & Development Milestones
Phase 1: 2005—2010
The R&D team conquered technical barriers in bulk production of
the
rare ginsenosides Rg3,Rh2,Rh1, aPPD,aPPT,etc.
Phase 2: 2010—2012
The R&D team conquered technical barriers in industrialized
production
of the more hard-to-obtain rare ginsenosides Rk1, Rk2, Rh3, Rg5, etc. We are now
the
first institution in the world possessing such technology.
Phase 3: 2012—2014
The R&D team conducted plenty of research in rare ginsenosides
Rk1,
Rk2, Rh3, Rg5, etc., and the results confirmed their roles in enhancing human
health.
Core Research and Development Team
Led by the Chinese Canadian Scientist
Peihua Yu PhD.
Devoted in phytomedicine research on Araliaceae ginseng species (Asian ginseng, American
ginseng, panax notoginseng, etc.), for more than 10 years, the team developed its own
proprietary technology that successfully conquered technical barriers in transforming
prototype ginsenosides in industrialized settings, thus yielding readily-absorbable and
effective rare ginsenosides.
Dan Deng
Chemical engineer
Canada Royal Enoch Phytomedicine Ltd. chief chemical engineer
Martin Wang
Ph.D. in Chinese medicine
Ph.D. in Chinese medicine, Nanjing University of Chinese Medicine
Post-doctoral fellow, Toyama Medical and Pharmaceutical University and Chinese
Medicine Research Institute
Muyuan (Sophie) Zhong
Msc in Pharmacology and Biomedical Toxicology
Msc in Pharmacology and Biomedical Toxicology, University of
Toronto.Core member of the R & D team
R&D Cooperation Partners
Sign Up and Save
Get first access to special offers releases.
Quality Guarantee
Secure Payment
Online Support
Express Shipping